Morgan Stanley Forecasts Strong Price Appreciation for Belite Bio (NASDAQ:BLTE) Stock

Belite Bio (NASDAQ:BLTE) had its price objective raised by investment analysts at Morgan Stanley from $191.00 to $201.00 in a report released on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley’s price objective points to a potential upside of 13.05% from the company’s current price.

Several other equities research analysts have also weighed in on BLTE. BTIG Research set a $187.00 price target on Belite Bio in a research note on Wednesday, December 3rd. Bank of America assumed coverage on Belite Bio in a research report on Monday, January 26th. They set a “buy” rating and a $195.00 price objective for the company. Cantor Fitzgerald upped their target price on shares of Belite Bio from $200.00 to $266.00 and gave the stock an “overweight” rating in a research report on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $185.00 price target on shares of Belite Bio in a research note on Wednesday, January 28th. Finally, Mizuho set a $223.00 price target on shares of Belite Bio in a research report on Thursday, February 19th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $202.33.

Belite Bio Trading Up 5.9%

NASDAQ:BLTE opened at $177.79 on Tuesday. Belite Bio has a 12 month low of $49.00 and a 12 month high of $200.00. The company has a 50-day moving average price of $169.39 and a 200-day moving average price of $123.68. The stock has a market cap of $6.67 billion, a price-to-earnings ratio of -77.30 and a beta of -1.46.

Belite Bio (NASDAQ:BLTE) last posted its earnings results on Monday, March 2nd. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.18. Equities analysts forecast that Belite Bio will post -1.17 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. EverSource Wealth Advisors LLC purchased a new stake in shares of Belite Bio during the second quarter valued at approximately $147,000. Marshall Wace LLP bought a new position in Belite Bio in the 2nd quarter valued at approximately $547,000. BNP Paribas Financial Markets purchased a new stake in Belite Bio during the 2nd quarter valued at $190,000. GAMMA Investing LLC increased its holdings in shares of Belite Bio by 11.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,758 shares of the company’s stock worth $130,000 after purchasing an additional 176 shares in the last quarter. Finally, High Net Worth Advisory Group LLC bought a new stake in shares of Belite Bio in the 3rd quarter worth $259,000. Institutional investors own 0.53% of the company’s stock.

More Belite Bio News

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: Cantor Fitzgerald sharply raised its price target to $266 (from $200) and kept an overweight rating — a large read-through that likely attracted buying interest. Belite Bio price target raised to $266 from $200 at Cantor Fitzgerald
• Positive Sentiment: Company reported DRAGON trial success and said tinlarebant is advancing toward FDA review — a clinical milestone that materially de‑risks the lead program and supports the higher valuations. Belite Bio Advances Tinlarebant Toward FDA Review After DRAGON Success
• Positive Sentiment: Multiple brokerages raised targets/ratings (Morgan Stanley, H.C. Wainwright among them), signaling fresh institutional support and helping momentum. (See H.C. Wainwright StreetInsider coverage.) Belite Bio PT Raised to $200 at H.C. Wainwright
• Positive Sentiment: Q4 2025 results topped EPS expectations (less-negative EPS) and management reiterated a Q2 2026 NDA target — the earnings call helped validate the timeline investors care about. Belite Bio Inc (BLTE) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Short-interest reports in early March appear anomalous/zero (NaN/0 values) and are unreliable as published — no clear evidence of a short squeeze or large persistent short position based on the available data.

About Belite Bio

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.